Brought to you by:
WAVE trial AVG cohort also benefits at six months with Wrapsody
Newly released six-month results from single-arm arteriovenous graft (AVG) cohort in the WAVE (Wrapsody arteriovenous access efficacy) trial showed target lesion and access circuit primary patency rates of nearly 82% and 68.8%, respectively. The latest data on the Wrapsody cell-permeable…
MVSS 2022: Research on hemodialysis access surgery attracts inaugural Midwestern Vascular disparities award
The authors behind a new study that found “significant differences” in hemodialysis vascular access outcomes after first-time arteriovenous (AV) fistula or graft creation “directly related” to a patient’s race said the findings speak “to an injustice within the field of vascular surgery.” The research…
AVeVA study confirms benefit of covered stent placement in graft-vein anastomotic stenosis treatment
A prospective, multicenter study involving the Covera vascular covered stent (BD) has confirmed the benefits of immediate, post-percutaneous transluminal angioplasty (PTA) placement of the device in treating arteriovenous graft (AVG) venous anastomotic stenosis when anatomically and clinically suitable. Writing in the Journal…
Risk of ‘feared’ ischemic steal syndrome comparable for tapered and non-tapered AVGs
In a recent systematic review and meta-analysis, Venkata Sai Jasty, from the University of Arizona College of Medicine in Tuscon, Arizona, and colleagues found that the risk of ischemic steal syndrome, “one of the most feared complications in vascular access,”…
New paradigm in arteriovenous grafts opens up possibility of novel cure for diabetes
A novel twist to arteriovenous graft platforms—traditionally the preserve of hemodialysis—has the ability to open up a new paradigm of treatment across a host of metabolic disorders like diabetes, a study to be presented at a scientific session on June…